Log In
Print
BCIQ
Print
Print this Print this
 

Curosurf, poractant alfa

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionPoractant alpha
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsTreat respiratory distress syndrome (RDS) in premature infants
Regulatory Designation
Partner Emerge Health Pty. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$205.3M

$205.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today